Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the above-referenced application. Kindly cancel Claim 52 and amend Claim 53-55, 57-60, and 62-63 as follows:

STATUS OF THE CLAIMS

1-51. (cancelled)

52. (CANCELLED)

53. (Currently amended) The method of claim 52, wherein the hydroxydiphonyl ether has A method of treatment for malaria, wherein the subject is infected with a malaria parasite, the method comprising the step of:

administering an antimalarial composition comprising a compound that is an inhibitor of fatty acid synthesis in the malaria parasite to the subject, wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether of the general formula 2 given below wherein the two phenyl rings (I & II) are joined by an oxygen atom (X=O) and either R_1 or R_2 represents a hydroxy (OH) group with the other being a hydrogen atom, respectively, or both being hydroxy groups, and wherein R_3 to R_{10} of the phenyl rings I and II are selected from the group consisting of: chlorine, bromine, iodine, hydrogen, hydroxyl groups, aldehyde groups, keto groups, and ester groups.

$$\begin{array}{c|c} R_{10} & & & \\ \hline R_{10} & & & \\ \hline R_{2} & & \\ \hline R_{7}R_{6} & & \\ \hline R_{5} & & \\ \hline \end{array}$$

Formula 2

54. (Currently amended) The method of claim 52.53, wherein the inhibitor of fatty acid synthesis is triclosan having formula 1 given below:

- 55. (Currently amended) The method of claim 52 53, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.
- 56. (previously presented) The method of claim 55, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.
- 57. (Currently amended) The method of claim 52.53, wherein the composition is administered by injection.
- 58. (Currently amended) The method of claim 52.53, wherein the amount of the inhibitor of fatty acid synthesis administered is in the dosage range of 0.03 mg/kg to 100 mg/kg.
- 59. (Currently amended) The method of claim 52.53, wherein the compound inhibits Fabl (enoyl ACP reductase) in the malaria parasite.
- 60. (Currently amended) The method of claim 52 53, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.
- 61. (previously presented) The method of claim 60, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.
- 62. (Currently amended) The method of claim 52.53, wherein the inhibitor of fatty acid synthesis in the malaria parasite is an inhibitor of Fabl (enoyl-ACP reductase).
- 63. (Currently amended) The method of claim 52.53, wherein the malaria parasite is P. falciparum.